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REVIEW CURRENTOPINION Neurostimulation for drug-resistant epilepsy: a
systematic review of clinical evidence for efficacy,
safety, contraindications and predictors for
response Copyright 
www.co-neurology.coma a a bPaul Boon , Elien De Cock , Ann Mertens , and Eugen TrinkaPurpose of review
Neurostimulation is becoming an increasingly accepted treatment alternative for patients with drug-resistant
epilepsy (DRE) who are unsuitable surgery candidates. Standardized guidelines on when or how to use
the various neurostimulation modalities are lacking. We conducted a systematic review on the currently
available neurostimulation modalities primarily with regard to effectiveness and safety.
Recent findings
For vagus nerve stimulation (VNS), there is moderate-quality evidence for its effectiveness in adults with drug-
resistant partial epilepsies. Moderate-to-low-quality evidence supports the efficacy and safety of deep brain
stimulation (DBS) and responsive neurostimulation (RNS) in patients with DRE. There is moderate-to-very
low-quality evidence that transcranial direct current stimulation (tDCS) is effective or well tolerated. For
transcutaneous vagus nerve stimulation (tVNS), transcranial magnetic stimulation (TMS) and trigeminal
nerve stimulation (TNS), there are insufficient data to support the efficacy of any of these modalities for DRE.
These treatment modalities, nevertheless, appear well tolerated, with no severe adverse events reported.
Summary
Head-to-head comparison of treatment modalities such as VNS, DBS and RNS across different epileptic
syndromes are required to decide which treatment modality is the most effective for a given patient
scenario. Such studies are challenging and it is unlikely that data will be available in the near future.
Additional data collection on potentially promising noninvasive neurostimulation modalities like tVNS, TMS,
TNS and tDCS is warranted to get a more precise estimate of their therapeutic benefit and long-term safety.
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DOI:10.1097/WCO.0000000000000534Epilepsy is a chronic neurological disorder affecting
up to 1% of the world population [1]. An estimated
one-third of these patients suffer from drug-resistant
epilepsy (DRE) as they fail to become seizure free or
suffer from unbearable side effects following antiep-
ileptic drug treatment [2]. Epilepsy surgery can lead
to seizure freedom in a well selected group of DRE
patients [3]. In a significant number of patients, the
epileptogenic zone cannot be identified or surgically
treated due to its localization within functional
brain tissue. For this group of patients, neurostimu-
lation is becoming an increasingly accepted treat-
ment alternative [4].
Today there are several neurostimulation
modalities available including well established
approaches such as vagus nerve stimulation© 2018 Wolters Kluwer ment alternatives such as transcutaneous vagus
nerve stimulation (tVNS), trigeminal nerve stimula-
tion (TNS), transcranial magnetic stimulation (TMS)
and transcranial direct current stimulation (tDCS)
are being investigated for the treatment of DRE inHealth, Inc. All rights reserved.
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KEY POINTS
 Neurostimulation is becoming an increasingly accepted
treatment alternative that should be evaluated in every
patient with DRE who is unsuitable for surgery.
 Low-to-moderate quality evidence supported the efficacy
and safety of VNS, DBS and RNS in patients with DRE.
 There is very low-to-moderate quality evidence that
tDCS is effective and well tolerated.
 tVNS, TMS and TNS appear well tolerated, but there
are currently insufficient data to support the efficacy of
any of these modalities for DRE.
 Head-to-head comparison of treatment modalities are
currently lacking, but will be required to decide which
treatment modality is the most effective for a given
patient scenario.
Neurostimulationfor drug-resistant epilepsy Boon et al.epilepsy centers around the world. There is, how-
ever, no standardized guideline on when or how
to use the various neurostimulation modalities
and there is no common consensus across epilepsy
centers.
In this study, we systematically reviewed each of
these neurostimulation modalities. For each neuro-
stimulation modality, we addressed two primary
questions: is the treatment efficacious? Is the treat-
ment well tolerated? We further addressed the
following two secondary questions: are there contra-
indications for the treatment? Are there predictors
for response to the treatment? The neurostimula-
tion modalities included in the current study were
VNS, deep brain stimulation (DBS), responsive neu-
rostimulation (RNS), tVNS, TMS, TNS and tDCS.
The systematic review is concluded with a deci-
sion model derived where possible from the evi-
dence reviewed and supplemented where needed
with empirical clinical experience of an expert panel
on neurostimulation for epilepsy.METHODS
The MEDLINE database was systematically searched
(14/2–2017) using the following search terms:
‘vagus nerve stimulation AND epilepsy’, ‘deep brain
stimulation AND epilepsy’, ‘responsive neurostimu-
lation AND epilepsy’, ‘cortical responsive stimula-
tion AND epilepsy’, ‘transcranial magnetic
stimulation AND epilepsy’, ‘transcutaneous vagus
nerve stimulation AND epilepsy’, ‘trigeminal nerve
stimulation AND epilepsy’ and ‘transcranial direct
current stimulation AND epilepsy’. Publication
inclusion criteria were studies or reviews reporting
seizure outcome data, quality of life (QoL) data and Copyright © 2018 Wolters Kluwe
1350-7540 Copyright  2018 Wolters Kluwer Health, Inc. All rights reseadverse events in DRE patients. The following study
types were subsequently excluded: nonsystematic
reviews, case-reports, retrospective studies with
exception of patient registry studies, prospective
open-label studies with less than 30 patients, and
randomized controlled trials (RCTs) with less than
10 patients. The literature collection strategy was
validated by having experts in the field of neuro-
stimulation for epilepsy (K.V. and P.B), who
selected, to their knowledge, two key publications
for each neurostimulation modality. When the
literature collection strategy had indeed managed
to collect all these key publications, the literature
collection strategy was deemed sufficiently compre-
hensive.
In all cases the highest level of evidence was
selected as the basis for answering the questions
under investigation. For primary questions concern-
ing safety and efficacy of the treatment, preexisting
systematic reviews of RCTs for each relevant neuro-
stimulation modality were selected in case these
fulfilled criteria specified below. In cases in which
no such review was found, original RCTs with more
than 10 patients actively treated were selected as
evidence basis. Preexisting systematic reviews were
only selected if they fulfilled the following eight
criteria: clearly defined questions or objectives with
provided answers to at least one of the primary
questions; methodologically transparent with sys-
tematic data collection and literature evaluation
according to a clearly specified protocol; the collec-
tion and evaluation of literature performed by more
than one independent investigator; application of
the GRADE scoring system for evaluation of the
quality of the evidence reviewed; excluding case
report evidence, retrospective evidence or prospec-
tive studies with less than 10 patients; including the
most recently published RCTs for the relevant neu-
rostimulation modality; the focus of the systematic
review on neurostimulation for epilepsy. The evalu-
ation of existing systematic reviews and extraction
of data from these was performed independently by
two independent experts.
For neurostimulation modalities in which no
preexisting systematic reviews met these criteria,
original RCTs with more than 10 patients actively
treated were used as evidence basis. RCTs were criti-
cally appraised with regard to bias risks according to
the GRADE procedure [5]. GRADE evaluation and
extraction of data was performed by two indepen-
dent experts.
Efficacy outcomes included change in seizure
frequency and responder rates (50% reduction in
seizure frequency) in the treated population relative
to a control population. To be deemed effective, a
neurostimulation modality should have a provenr Health, Inc. All rights reserved.
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Seizure disordersstatistically significant effect on one of these out-
comes. As neurostimulation is currently indicated
in unsuitable surgery candidates, seizure freedom
rates were not investigated. The safety assessment
focused on the rate of adverse events, in particular
serious adverse events, in the treated population
relative to the control population. In addition to
these outcomes changes in QoL, cognitive and
mood outcomes were extracted where available.
Addressing secondary questions was attempted
when there was evidence to support both the effi-
cacy and safety of a given neurostimulation modal-
ity. To investigate the secondary questions, the
evidence available was reviewed in the following
order: preexisting systematic reviews with meta-
analyses of RCTs; original RCTs; reviews of prospec-
tive patient registries and original prospective open-
label studies with more than 30 patients. When
several studies examined the same specific contra-
indication or predictor for response to treatment,
the highest level of evidence according to the clas-
sification above was used to review the question.
Initially studies were screened for information
relevant for the secondary questions by two inde-
pendent experts. Studies containing information
relevant for the two secondary questions were sub-
jected to a full evaluation according to the GRADE
approach by two independent experts. A contrain-
dication for a treatment was defined as a patient
characteristic which is associated with a higher risk
of mortality or a higher occurrence of adverse events
relative to a control group, characterized by other
patient characteristics, receiving the same treat-
ment. Similarly, predictors of response were defined
as patient characteristics predicting a better thera-
peutic outcome in terms of general seizure fre-
quency reduction, treatment response (50%
seizure frequency reduction), QoL improvements
or mood improvements relative to a control group,
characterized by other patient characteristics,
receiving the same treatment. To qualify for inclu-
sion in the following assessment, studies required
the availability of a statistical comparison of treat-
ment outcomes between at least two patient groups
with clearly defined differing patient characteristics
receiving the same treatment. Patient characteristics
were only considered if these were assessable prior
to treatment application (e.g. epilepsy type, cause,
comorbidities, demographics etc.).VAGUS NERVE STIMULATION
The search ‘vagus nerve stimulation AND epilepsy’
yielded a total of 1262 hits of which 470 publica-
tions met the inclusion criteria. Following applica-
tion of exclusion criteria, nine systematic reviews Copyright © 2018 Wolters Kluwer 
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try studies [6,46–61] were evaluated as a basis for
answering primary and secondary questions for
VNS. The majority of these studies were based on
the VNS therapy patient outcome registry that
included over 5000 patients. Following critical eval-
uation of the nine systematic reviews, two system-
atic reviews [7,8] met the criteria for inclusion and
were used as a basis to examine the primary ques-
tions regarding efficacy and safety. For VNS, second-
ary questions regarding contraindications and
predictors for response were reviewed on the basis
of three prospective studies [19,26,27] and 11 regis-
try studies [6,46,47,50,52,54–57,59,60].Efficacy and safety of vagus nerve
stimulation
Chambers and Bowen [8] conducted ameta-analysis
on the at least 50% reduction in seizure frequency
outcome based on the three RCTs in adults
[40,42,43] and one RCT in children (<18 years)
[39] with focal DRE. All trials compared a high-
stimulation paradigm (assumed therapeutic dose)
with a low-stimulation paradigm (assumed subther-
apeutic dose). RCTs in children and adults were
evaluated separately. In the analysis of the adult
population, Chambers et al. found that, during
the blinded period (3 months–16 weeks), patients
treated with the high-stimulation paradigm were
more likely to achieve a at least 50% reduction in
seizure frequency than patients treated with the
low-stimulation paradigm. This was reflected by
an odds ratio (OR) of 1.95 [95% confidence interval
(CI): 1.16–3.27] in favor of the high-stimulation
paradigm, rated as moderate-quality evidence.
Two of the RCTs [42,43] reported significant reduc-
tions in seizure frequency in the high-stimulation
groups at the end of the blinded period, relative to
the low-stimulation group. This evidence was rated
as low in quality. In contrast, the RCT in children
[39], rated as low-quality evidence, could not dem-
onstrate the effectiveness of VNS.
Panebianco et al. [7] pooled four RCTs
[37,39,42,43] in both children and adults with par-
tial epilepsies in one meta-analysis to assess the
likelihood to achieve a at least 50% reduction in
seizure frequency. The result was anOR of 1.73 (95%
CI: 1.13–2.64) in favor of the high-stimulation par-
adigm (assumed therapeutic dose) over a low-stim-
ulation paradigm (assumed subtherapeutic dose).
The evidence was rated as moderate in quality.
Panebianco et al. further evaluated the safety of
VNS by conducting meta-analyses to estimate the
relative risk (RR) of adverse events between the high-
stimulation group and low-stimulation groups. OnHealth, Inc. All rights reserved.
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Neurostimulationfor drug-resistant epilepsy Boon et al.the basis of three RCTs [37,42,43] a RR of 2.17 (99%
CI: 1.47–3.17) was found for voice alteration or
hoarseness and a RR of 1.09 (99% CI: 0.74–1.62)
was found for cough. Both outcomes were rated as
moderate in evidence quality. Based on two RCTs
[42,43], a RR of 2.45 (99% CI: 1.07–5.60) was found
for dyspnea, rated as low quality of evidence. Based
on the same two RCTs, RRs of 1.01 (99% CI: 0.60–
1.68) and 0.78 (99% CI: 0.39–1.53) were found for
pain and paresthesias, respectively. Both outcomes
were rated as moderate in evidence quality. Finally,
nausea was reported with a RR of 0.89 (99% CI:
0.42–1.90) and headache with a RR of 0.90 (0.48–
1.69). Evidence quality was not specified for these
two outcomes.
Though Chambers and Bowen [8] did not con-
duct anymeta-analyses on safety outcomes, similar
adverse events were reported in the safety review
of VNS in both children and adults. Chambers
et al., however, did report on rare adverse events,
including two cases of vocal cord paralysis and two
cases of lower facial muscle paresis, three cases of
postsurgical infection and one case of fluid accu-
mulation over the pulse generator, which required
intervention.
In conclusion, there is low-to-moderate quality
evidence that VNS is well tolerated in both children
and adults with drug-resistant partial epilepsies,
whereas there is moderate quality evidence for the
effectiveness of VNS in adults with drug-resistant
partial epilepsies.Contraindications and predictors for
response
The systematic review of literature revealed that
there are currently no concrete data to suggest
any contraindications for VNS. Some authors and
previously published guidelines endorsed by the
American Academy of Neurology [9], have however
suggested caution when applying VNS in patients
with preexisting apnea disorders due to previously
reported adverse effects of VNS on respiration.
Predictors of response to VNS have been studied
in a few prospectively conducted studies [19,26,27].
The vast majority of the evidence included in the
present review, however, is from patient registry
studies [6,46,47,50,52,54–57,59,60], based on the
same patient registry managed and maintained by
themanufacturer of the commercially available VNS
system, LivaNova (formerly known as Cyberonics).
Although the registry data have been acquired pro-
spectively, all studies retrospectively investigate the
data, which subjects the data to several likely flaws.
The evidence presented in the following is thus all
rated as very low quality. Copyright © 2018 Wolters Kluwe
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with superior efficacy in children compared with
the adult population. This is supported by two pro-
spective studies [19,27] and the registry studies
[47,59]. However, it should be noted that the only
RCT currently conducted in the pediatric popula-
tion found no effect of VNS on seizure outcomes
within the 20-week blinded period [39], whereas
another prospective data set found no difference
in treatment effect between children and adults
[26]. Shorter duration of epilepsy before VNS
implantation is another factor found to predict
favorable seizure control outcomes in both prospec-
tive studies [27] and registry studies [6,47,50,59],
supporting early application of VNS. It should fur-
ther be mentioned that marginally superior seizure
control is seen in patients who have not previously
had intracranial epilepsy surgery [57].
With regard to epilepsy type, results are more
conflicting. Recent registry studies have suggested a
marginally superior effect of VNS, both with regard
to seizure control and QoL outcomes, in generalized
epilepsies [6,46]. An earlier registry study from
the same author, on the other hand, found that
generalized (primarily or secondarily) tonic–clonic
seizure types predicted a worse outcome [47]. Dis-
agreements have also been found between other
studies in which one study suggested superior
seizure control in patients with focal or partial
epilepsies [26] and another study reported a larger
improvement in seizure control in severe multifocal
epilepsies [27]. This outcome is thus currently
inconclusive.
The cause of epilepsy has also been studied as a
potential predictive factor for improved seizure con-
trol during VNS, in which conflicting results also
have been reported. A registry study recently found a
higher response rate (RR) in nonlesional epilepsy [6],
whereas a prospective study previously reported a
higher RR among patients with lesional epilepsies
compared with those with cryptogenic epilepsies
[27], though the comparisons may not be similar.
Patients with brain tumors were found to respond
similarly to VNS as patients without brain tumors
[52]. Finally, underlying neuronal migration disor-
der has been associated with a less favorable seizure
control [26] and patients with postinfectious epi-
lepsy have been found to respond better to VNS than
patients with cortical malformations [27].DEEP BRAIN STIMULATION
The search ‘deep brain stimulation AND epilepsy’
yielded a total of 794 hits of which 218 publications
met the inclusion criteria (Fig. 1). Following appli-
cation of exclusion criteria, five systematic reviewsr Health, Inc. All rights reserved.
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FIGURE 1. Flowchart of the literature collection for deep brain stimulation. OL, open label; RCT, randomized controlled trial.
Seizure disorders[8,62,63,64
&&
,65], two RCTs [66,67] and two pro-
spective open-label study [68,69] were evaluated
as a basis for answering primary and secondary
questions for DBS. Following critical evaluation of
the five systematic reviews, two systematic reviews
[8,64
&&
] were found to meet the criteria for inclusion
and were used as a basis to examine the primary
questions regarding efficacy and safety. For DBS,
secondary questions regarding contraindications
and predictors for response were reviewed on the
basis of one RCT [66] and one open-label study [68].Efficacy and safety
Both Chambers and Bowen [8] and Sprengers et al.
[64
&&
] assessed the efficacy and safety of anterior
thalamic nucleus (ANT) DBS based on only one
RCT in the adult population with DRE [66]. During
a 3-month blinded period, ANT DBS was found to
significantly decrease seizure frequency in patients Copyright © 2018 Wolters Kluwer 
202 www.co-neurology.comreceiving active DBS relative to patients receiving
sham DBS. Chambers and Bowen [8] rated the evi-
dence quality of this outcome as low due to high
risks of imprecision bias, due to incomplete report-
ing of variability around effect estimates and insuf-
ficient powering. Chambers further estimated a
high risk of publication bias, as the RCT [66] failed
to fully report all outcomes assessed, as there was
only one RCT available, which further was funded
by the device manufacturer. Though Sprengers et al.
[64
&&
] did not point out the possibility of impreci-
sion bias, they did acknowledge the incomplete
reporting of outcomes, but chose not to downgrade
the evidence quality. Sprengers et al. [64
&&
] further
added that there is a likely underestimation of the
effect size during the relatively short blinded period
of the study, as efficacy has been observed to
increase over time. Sprengers et al. [64
&&
] thus rated
the evidence quality of this outcome as high.
According, to the guidelines applied for GRADE inHealth, Inc. All rights reserved.
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Neurostimulationfor drug-resistant epilepsy Boon et al.the current study, a downgrade to at least moderate
quality for likely publication bias would have been
applied for this outcome.
Both systematic reviews [8,64
&&
] additionally
assessed the responder rate as an efficacy outcome
based on the same RCT [66] and reported a nonsig-
nificant OR of 1.20 (95% CI: 0.52–2.80) in favor of
active DBS. Chambers et al. rated the evidence qual-
ity of the outcome as low with the same concerns as
mentioned in the paragraph above. Sprengers et al.
[64
&&
], rated the evidence quality of this outcome as
moderate, estimating that more studies with more
patients are required to obtain a more precise esti-
mate of treatment efficacy.
Sprengers et al. [64
&&
] further assessed the safety
of DBS in the blinded period of the included RCT
rating all safety outcomes as moderate in quality,
with the comment that additional studies are
required to obtain a more precise estimate of the
adverse event profile. Two adverse events were
reported at a significantly higher rate in the active
DBS group relative to the sham DBS group: self-
reported depression (14.8 vs. 1.8%) and self-reported
memory impairment (13.0 vs. 1.8%). Other adverse
events reported at an insignificant, but numerically
higher rate included confusional state, anxiety and
paresthesia. On the other hand, significantly fewer
epilepsy-related injuries were reported in the active
DBS group (7.4 vs. 25.5%).
In conclusion, low-to-moderate quality evidence
suggests that ANT DBS is well tolerated and effective
in the treatment of DRE in the adult population.Contraindications and predictors for
response
The systematic review of literature revealed no data
to support any contraindications of ANT DBS. Nev-
ertheless, caution has been suggested for application
of DBS in patients with concomitant mood or mem-
ory disorders, due to the adverse effects of ANT DBS
reported in these domains [66].
There are additionally very limited data avail-
able on predictors of response to ANT DBS. Seizure
outcome data obtained from the only RCT studying
ANT DBS [66] and the open-label prospective 5-year
follow-up study [68] were stratified for patient char-
acteristics such as epilepsy type and prior treatment
history. There are serious limitations to these data,
due to which the outcomes presented in the follow-
ing have been rated as very low in evidence quality.
In the 5-year follow-up study by Salanova et al. [68],
a median reduction of 76% in seizure frequency was
observed in patients with temporal lobe epilepsy
after 5 years of ANT DBS. In comparison, median
seizure frequency reductions of 59 and 68% were Copyright © 2018 Wolters Kluwe
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classified as ‘frontal lobe epilepsy’ and ‘other epi-
lepsy types’, respectively. Despite numerical differ-
ences in the observed effects, there were no head to
head comparisons of the groups making it difficult
to draw definitive conclusions. The same 5-year
open-label study [68] noted that ANT DBS was
equally effective in patients with a history of either
prior VNS treatment or epilepsy surgery as in
patients where none of these treatments had been
previously applied.Other types of deep brain stimulation
Sprengers et al. further reviewed the efficacy and
safety of the less conventional hippocampal, cen-
tromedian thalamic nucleus and cerebellar DBS. A
meta-analysis of hippocampal DBS based on three
very small RCTs [70–72] with sample sizes of 4, 8
and 9, respectively, described hippocampal DBS as
effective in reducing seizure frequency in patients
with mesial temporal lobe epilepsy relative to sham
DBS. The quality of evidence of this outcome was
rated asmoderate. There was no significant effect on
the responder rate, an outcome that was rated as low
in evidence quality. The limited number of patients
included in the studies limits both outcomes.
Stimulation-related adverse events were not
reported in these trials, with the outcome rated as
low in evidence quality.
For centromedian thalamic nucleus and cerebel-
lar DBS, Sprengers et al. [64
&&
] concluded that the
current evidence, rated as very low-to-low in quality,
cannotdemonstrate statistically significant effects for
seizure outcomes. Stimulation-related adverse events
were not reported at significant rates, but these out-
comeswere similarly rated as low in evidence quality.RESPONSIVE NEUROSTIMULATION
The search ‘responsive neurostimulation AND epi-
lepsy’ yielded a total of 93 hits of which 46 publi-
cations met the inclusion criteria. Following
application of exclusion criteria, two systematic
reviews [62,64
&&
] and five prospective open-label
studies [73,74,75
&
,76,77] remained. The search was
merged with the search ‘cortical responsive stimu-
lation AND epilepsy’, which yielded a total of 101
hits, with 28 publications meeting the inclusion
criteria. Following application of exclusion criteria,
two systematic reviews [62,64
&&
], two prospective
open-label studies [73,74] and one RCT [78]
remained. Merging the two searches resulted in a
total of two systematic reviews [62,64
&&
], five pro-
spective open-label studies [73,74,75
&
,76,77] and
one RCT [78], which were evaluated as basis forr Health, Inc. All rights reserved.
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Seizure disordersanswering primary and secondary questions for
RNS. Following critical evaluation of the two sys-
tematic reviews, one systematic review [64
&&
] was
found tomeet the criteria for inclusion andwas used
as a basis to examine the primary questions for RNS.
For RNS, secondary questions regarding contraindi-
cations and predictors for response were reviewed




Efficacy and safety was reviewed by Sprengers et al.
[64
&&
] based on the only RCT published on RNS [78].
The trial compared active RNS with a sham stimula-
tion protocol in a 3-month blinded period in adults
with drug-resistant focal/multifocal epilepsy. Rela-
tive to sham, active RNS was associated with a
significant reduction in seizure frequency, an out-
come, whichwas rated as high in evidence quality. It
was further argued that treatment efficacy could be
underestimated in this trial, due to the short dura-
tion of the blinded period. It should be noted,
however, that this outcome is based on only one
study, which is initiated, directed and funded by
investigators with affiliations to themanufacturer of
the device. According to the guidelines used to
evaluate the evidence quality of outcomes in the
present systematic review that would usually lead to
a recommendation of downgrading the evidence
quality to moderate. The RCT [78] further found
no significant effect of RNS on the responder rate
outcome, which Sprengers et al. [64
&&
] rated as an
outcome of moderate evidence quality.
Sprengers et al. [64
&&
] further evaluated the safety
of RNS based on the same RCT and concluded that
moderate quality evidence indicated that there is no
difference in stimulation-related adverse events
between actively RNS treated patients and sham
treated patients. A concern was however raised with
regard to the sudden unexplained death in epilepsy
(SUDEP) rate, which was higher than usually
reported for epilepsy patients (11.8 per 1000 vs.
2.2–10 per 1000). Due to the limited number of
patients reported (n¼191) the authors refrained
from making definitive conclusions on the SUDEP
issue.
In conclusion, moderate-quality evidence sup-
ports the effectiveness and safety of RNS in the
treatment of drug-resistant focal/multifocal epilep-
sies in that adult population.Contraindictions and predictors for response
The systematic review of literature revealed no data
to support concrete contraindictions for RNS, Copyright © 2018 Wolters Kluwer 
204 www.co-neurology.comalthough a prerequisite for application of RNS is
the ability to localize the ictal onset zone/zones.
Predictors for response to RNS were examined in
an open-label extension to the original RCT [74].
Though there was no comparison with other patient
groups, it was clear that 75% of the 16 patients
becoming seizure free during the 2-year open-label
extension period were patients with only one sei-
zure focus, a finding which was found unlikely to
have occurred by chance. Further, it was clear that
patients responding to RNS were typically younger
than those not responding. A comparison of various
seizure types found no meaningful differences in
seizure control outcomes. Due to obvious limita-
tions of the evidence presented, the evidence qual-
ity was rated as very low.
In parallel with these findings, two other studies
published mood and cognitive outcomes from the
open-label extension trial [76,77]. Both studies strat-
ified for seizure type of either neocortical or mesial
temporal lobe origin. Improved verbal memory per-
formance was found following RNS in patients with
neocortical epilepsies, but not in patients with
mesial temporal lobe epilepsies [76]. In contrast,
overall improvement in memory performance was
observed in patients with mesial temporal lobe epi-
lepsy but not in patients with neocortical epilepsies
[76]. The other study [77] similarly stratified for
seizure type but found no difference in effects on
QoL or mood outcomes. The reported results are
clearly limited by the lack of a direct comparison of
the two groups and the evidence quality was rated as
very low.TRANSCUTANEOUS VAGUS NERVE
STIMULATION
The search ‘transcutaneous vagus nerve stimulation
AND epilepsy’ yielded a total of 49 hits of which 16
publications met the inclusion criteria. Following
application of exclusion criteria, one prospective
open-label study [79] and fourRCTs [80
&
,81–83]were
evaluated as a basis for answering primary and sec-




basis to examine the primary questions regarding
efficacy and safety. The remaining three RCTs [81–
83] and the one prospective open-label study [79]
were not considered in the present review as the
neurostimulation technique applied in these studies
was not fully disclosed and is not available in Europe.Efficacy and safety
The efficacy and safety of tVNS in adults with DRE
was evaluated by Bauer et al. [80
&
], in a RCT in whichHealth, Inc. All rights reserved.
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Neurostimulationfor drug-resistant epilepsy Boon et al.a high-stimulation paradigm (assumed therapeutic
dose) and a low-stimulation paradigm (assumed
subtherapeutic dose, used as control) were com-
pared across a 20-week blinded period. Though a
reduction in seizure frequency was observed within
the high-stimulation group, the effect was not sta-
tistically significant different to the effect observed
within the low-stimulation group. Furthermore,
there was no difference in responder rate between
the two groups. Due to several potential biases in the
study the evidence quality of these outcomes were
rated as very low.
Adverse events occurring at a higher rate in the
high-stimulation group than in the low-stimulation
group included headache, ear pain, erythema at the
stimulation application site, vertigo, and nausea.
The rate of adverse events was not compared sta-
tistically. No serious adverse events were reported to
occur at a higher rate in the high-stimulation group.
All safety outcomes were similarly rated as very low
in evidence quality.
In conclusion, there are currently insufficient
data to consider tVNS as an effective treatment for
DRE (very low-quality evidence), though tVNS
appears well tolerated (very low-quality evidence).
Due to the lack of efficacy data for tVNS, secondary
questions were not evaluated for tVNS.TRANSCRANIAL MAGNETIC STIMULATION
The search ‘transcranial magnetic stimulation AND
epilepsy’ yielded a total of 568 hits of which 92
publications met the inclusion criteria. Following
application of exclusion criteria, five systematic
reviews [62,84,85,86
&
,87] and seven RCTs [88–94]
were evaluated as a basis for answering primary and
secondary questions for TMS. Following critical
evaluation of the five preexisting systematic
reviews, one systematic review [84] was found to
meet the criteria for inclusion andwas used as a basis
to examine the primary questions regarding efficacy
and safety. The analysis in the following is limited to
repeated TMS (rTMS) paradigms.Efficacy and safety
Chen et al. [84] reviewed the efficacy and safety
based of TMS for the treatment of DRE based on
seven RCTs [90–96]. Six of the studies [90–95] com-
pared an assumed therapeutic rTMS paradigm with
either placebo or an active assumed ineffective rTMS
paradigm. One study [96] compared an rTMS para-
digm with conventional antiepileptic drug therapy.
All studies included patients with complex partial or
secondarily generalized seizures. Due to differences
in the intervention procedure, outcome measures Copyright © 2018 Wolters Kluwe
1350-7540 Copyright  2018 Wolters Kluwer Health, Inc. All rights reseand study designs, a meta-analysis was not con-
ducted and instead studies were evaluated and sum-
marized per study.
Overall, two studies [89,92] showed a reduction
in seizure frequency following rTMS within the
actively treated group, whereas no such effects were
observed in the control groups. A clear weakness of
these outcomes, however, was that the actively
treated groups were not directly compared with
the control groups. Another study [93] found a
similar reduction in seizure frequency within the
actively treated group, but when compared with the
placebo group there was no difference in treatment
effect. Four other studies [90,91,94,96] found
changes in seizure frequency in treatment groups
or control groups. Although two studies seemingly
report improved seizure control following rTMS, the
outcome was deemed inconclusive. The evidence
quality of this outcome was rated as low, due to
unclear reporting on study designs and likely impre-
cision due to insufficient powering of studies.
Three of the included studies [90–92] addition-
ally reported responder rate as an outcome. One
study [92] found significantly more responders in
the actively treated group than the control group.
The other two studies [90,91], however, found no
difference in the responder rate between the groups.
Thus again, the outcome was considered inconclu-
sive. The evidence quality of the outcome was simi-
larly rated as low.
Based on the same seven studies, Chen et al. [84]
reviewed the safety of rTMS inDRE patients. None of
the studies reported any adverse events occurring at
statistically significant higher rates in the treatment
groups relative to the control groups. Nevertheless,
numerical differences in adverse events were
reported between treatment and control groups,
with the most frequently reported adverse events
being headache and dizziness. One study [94]
reported a seizure during treatment. Other serious
adverse events were not reported. The evidence
quality of adverse events outcomes was not rated
in this case, but it was presumably similar to previ-
ously reported outcomes as the same limitations
apply.
In summary, there are currently insufficient
data available to definitively conclude whether
rTMS is effective in the treatment of DRE (low-
quality evidence). Low-quality evidence would,
however, suggest rTMS as a well tolerated treatment
alternative.TRIGEMINAL NERVE STIMULATION
The search ‘trigeminal nerve stimulation AND
epilepsy’ yielded a total of 80 hits of which 17r Health, Inc. All rights reserved.
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application of exclusion criteria one RCT [97] and
one prospective open-label study [98] were evalu-
ated as a basis for answering primary and secondary
questions for TNS. The one RCT [97] was used as
basis for examining the primary questions regarding
efficacy and safety.Efficacy and safety
DeGiorgio et al. [97] studied both the efficacy and
safety of TNS in a RCT, which compared a high-
intensity TNS paradigm with an active control low-
stimulation paradigm (assumed subtherapeutic
dose). Patients included were all DRE patients with
complex partial or generalized tonic–clonic seiz-
ures. Over an 18-week blinded period, a significant
reduction in seizure frequency was found in the
treated group. Although no change was observed
in the active control group, there was no statistically
significant difference between the groups. Similarly,
there was no difference in the RR between the TNS
treated group and the active control group. Both
outcomes were rated as low in evidence quality. TNS
was further found to improve mood in both groups,
though significantly more in the TNS treated group.
This outcome was rated as low in evidence quality.
The RCT [97] did not reported whether any
adverse events occurred at a higher rate in the
TNS treated group relative to the active control
group. Adverse events such as anxiety (4% of
patients), skin irritation (14% of patients) were how-
ever reported as device-related adverse events. It
should further be noted that there was significant
elevation in blood pressure within the TNS treated
group at the first follow-up after 6 weeks of treat-
ment, which was not noted at other follow-up visits.
No serious adverse events were reported in the
course of the study. The quality of evidence of the
safety outcomes was rated as low.TRANSCRANIAL DIRECT CURRENT
STIMULATION
The search ‘transcranial direct current stimulation
AND epilepsy’ yielded a total of 72 hits of which
26 publications met the inclusion criteria. The
search was merged with the search ‘cathodal DC
AND epilepsy’ which yielded a total of two hits, both
meeting the inclusion criteria. Following applica-
tion of exclusion criteria two systematic reviews
[62,99
&
] and eight RCTs [100–107] were evaluated
as a basis for answering primary and secondary
questions for tDCS. Evaluation of the two preexist-
ing systematic reviews according to the criteria for
inclusion deemed both invalid and hence the eight Copyright © 2018 Wolters Kluwer 
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the primary questions regarding efficacy and safety.
The present analysis of evidence further focused
on cathodal tDCS, leading to the exclusion of
additional two RCTs [104,105] focusing mainly on
cognitive benefits of anodal tDCS.Efficacy and safety
Due to variability in study designs (parallel group vs.
cross over designs), stimulation parameters, appli-
cation site of stimulation and patient groups
included a meta-analysis of effects of tDCS on sei-
zure frequency or responder rate was not conducted.
Instead the evidence will be summarized and the
evidence quality judged separately for each study
included.
Three studies [100,102,107] assessed the effect of
a single 20-min session of cathodal tDCS applied
over the area in which interictal discharges dis-
played the highest amplitude. Two of the studies
were sham-controlled, parallel group studies. One
study [107] assessed effects of tDCS in DRE patients
with cortical malformations, whereas the other
study [102] examined effects in children (6–15 years
old) with simple partial or complex partial with/
without secondary generalization. Though both
studies [102,107] found a significant reduction in
the frequency of epileptic discharges in the hours
following tDCS application, no effect was found on
seizure frequency over the following month. The
quality of evidence of outcomes from these studies
was judged as very low [107] and moderate [102],
respectively. These findings are in sharp contrast to
the third study, which was a smaller (n¼10) cross
over study, using the same tDCS paradigm (i.e.
20min, one session) to assess anticonvulsant effects
in patients with drug-resistant temporal lobe epi-
lepsy. Here a significant reduction in seizure fre-
quency was found in the week following active
tDCS (71%) relative to the sham condition
(þ25%). The quality of evidence reported in this
study [100] was estimated as very low. Apart from
itching over the active stimulation site during tDCS,
the only adverse event reported was a single occur-
rence of a skin rash under the anode, which resolved
in the days following treatment.
Threeother studies [101,103,106] examinedanti-
convulsant effects of three to five sessions each con-
sisting of 30min of cathodal tDCS sessions split
on consecutive days. A cross over study [103] in
patients with drug-resistant Lennox–Gastaut syn-
drome found that five sessions of tDCS on consecu-
tive days dramatically reduced seizure frequency by
93% on the 5th day of tDCS, which differed signifi-
cantly from the observations made in the shamHealth, Inc. All rights reserved.
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reduced (56%) 4 weeks after initiating tDCS treat-
ment. In this case, the cathode was placed over the
left M1 area in all cases. The evidence quality
of outcomes from this study was estimated as
moderate.
The final two studies [101,106] both examined
patients with drug-resistant mesial temporal lobe
epilepsy and hippocampal sclerosis. One study
[106] was a sham-controlled cross-over study, in
which tDCS was applied over three sessions sched-
uled on consecutive days with a 12-Hz sinusoidal
current. The cathode was placed over the temporal
lobe pathologically affected by hippocampal sclero-
sis. Over the month following tDCS treatment, an
average seizure frequency reduction of 84% was
observed relative to baseline, whereas no difference
was observed in the sham condition. Ten of 12
patients were classified as responders and six
patients were seizure free following tDCS. The evi-
dence quality of outcomes in this study was esti-
mated as very low. The final study was a sham-
controlled parallel group designed study in which
tDCS was applied over three sessions on consecutive
days in one group and five sessions on consecutive
days in another group. A constant cathodal current
was applied over the area displaying the largest
amplitude of interictal epileptic spikes. Following
three and five sessions of tDCS, significant seizure
frequency reductions of 44 and 55% were observed
2 months after tDCS treatment, respectively. These
changes were significantly different from the sham
condition. This outcome was estimated as moderate
in evidence quality.
Repeated applications of tDCS on consecutive
days were associated with few adverse events. One
study did not report adverse events [106], whereas
another study [103] only reported on the occurrence
of a skin burn under the reference electrode, which
rapidly healed. The final study reported a mild itch
during tDCS in 90% of patients and two incidences
of moderate headache in the hours following tDCS
[101].
In conclusion, very low-to-moderate quality evi-
dence was not able to demonstrate consistent anti-
epileptic effects of a single session of tDCS. A single
session of tDCS, however was not associated with
any serious adverse events. Very low-to-moderate
quality evidence demonstrated a reduction in sei-
zure frequency following three or five sessions of
tDCS applied on consecutive days. No serious
adverse events were reported. The evidence is cur-
rently limited to patients with specific epilepsy syn-
dromes, such as patients with mesial temporal lobe
epilepsy with hippocampal sclerosis or patients with
Lennox–Gastaut syndrome. Due to a lack of studies Copyright © 2018 Wolters Kluwe
1350-7540 Copyright  2018 Wolters Kluwer Health, Inc. All rights reseincluding patients with more diverse epilepsy syn-
dromes, secondary questions were not evaluated
for tDCS.FINAL JUDGEMENT
Low-to-moderate quality evidence supported the
efficacy and safety of VNS, DBS and RNS in patients
with DRE. There is very low-to-moderate quality
evidence that repeated tDCS is effective in reducing
seizures in patients with both mesial temporal lobe
epilepsy and hippocampal sclerosis and in patients
with Lennox–Gastaut syndrome. Similarly, very
low-to-moderate quality evidence suggests that
tDCS is well tolerated in this population of patients.
For tVNS, TMS and TNS, there are currently insuffi-
cient data to support the efficacy of any of these
modalities in the treatment of DRE (low to very
low-quality evidence). These treatment modalities,
nevertheless, appear well tolerated, with no severe
adverse events reported (very low-to-low-quality
evidence).
There are currently no definitive data to suggest
any contraindications to any of the neurostimula-
tion modalities. Nevertheless, caution has been sug-
gested for applying VNS in patients with apnea
disorders or application of DBS in patients with
mood or memory disorders as these treatments
may exacerbate symptoms. RNS requires the ability
to identify one or more ictal onsets.
Very low-quality evidence further suggested
that a shorter history of seizures and no prior intra-
cranial epilepsy surgery were predictors of favorable
response to VNS. Analyses stratifying for other
patient demographics, epilepsy type or epilepsy
cause, were inconclusive. Similar analyses were
unavailable for any of the modalities proven effec-
tive (DBS or RNS). Predictors to tDCS were not
considered due to a lack of studies including
patients with more diverse epilepsy syndromes. As
similar data are not available for DBS or RNS, it is
impossible to conclude whether indicated predic-
tors for response to VNS are selective to VNS, or
whether these patients simple constitute an ‘easier
to treat’ population of patients.
Additional data collection on potentially prom-
ising noninvasive neurostimulationmodalities such
as tVNS, TMS, TNS and tDCS is warranted to compile
a more precise estimate of their therapeutic benefit
and long-term safety.
Further, acquisition of data sets allowing head-
to-head comparison of treatment modalities such as
VNS, DBS and RNS across different epileptic syn-
dromes are required to decide which treatment
modality is the most effective for a given patient
scenario.r Health, Inc. All rights reserved.
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